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Identity 
Other names: CD191, CKR-1, CKR1, CMKBR1, 
HM145, MIP1aR, SCYAR1 




CCR1, a member of the beta chemokine receptor 
family, is a seven transmembrane protein similar to G 
protein-coupled receptors. CCR1 is the first human CC 
chemokine receptor to be identified at the cDNA level. 
It has a functional viral homolog, US28, which is a 
human cytomegalovirus.The ligands of this receptor 
include macrophage inflammatory protein 1 alpha 
(MIP-1 alpha), regulated on activation normal T 
expressed and secreted protein (RANTES), monocyte 
chemoattractant protein 3 (MCP-3), and myeloid 
progenitor inhibitory factor-1 (MPIF-1). This gene and 
other chemokine receptor genes, including CCR2, 
CCRL2, CCR3, CCR5 and CCXCR1, form a gene 
cluster on chromosome 3p. 
Description 
Sequence length: 6633 bp; coding sequence: CDS 72-
1139. 2 exons; number of SNPs: 97. 
Transcription 
2690 bp mRNA, no alternative splicing. 
Pseudogene 
No pseudogenes have been reported for CCR1. 
Protein 
Note 
Chemokine receptors are cytokine receptors found on 
the surface of certain cells, which interact with a type 
of cytokine called a chemokine. They each have a 7 
transmembrane structure and couple to G-protein for 
signal transduction within a cell, making them 
members of a large protein family of G protein-coupled 
receptors. Following interaction with their specific 
chemokine ligands, chemokine receptors trigger a flux 
in intracellular calcium (Ca
2+
) ions (calcium signaling). 
This causes cell responses, including the onset of a 
process known as chemotaxis that traffics the cell to a 
desired location within the organism. 
 
 






Atlas Genet Cytogenet Oncol Haematol. 2011; 15(1)  2 
 
Predicted structure and amino acid sequence of CCR1. The typical serpentine structure is depicted with three extracellular (top) and 
three intracellular (bottom) loops and seven transmembrane domains. The shaded horizontal band represents the cell membrane. Amino 
acids are listed with a single letter code. 
 
Chemokine receptors share many common structural 
features; they are composed of about 350 amino acids 
that are divided into a short and acidic N-terminal end, 
seven helical transmembrane domains with three 
intracellular and three extracellular hydrophilic loops, 
and an intracellular C-terminus containing serine and 
threonine residues that act as phosphorylation sites 
during receptor regulation. The first two extracellular 
loops of chemokine receptors are linked together by 
disulfide bonding between two conserved cysteine 
residues. The N-terminal end of a chemokine receptor 
binds to chemokine(s) and is important for ligand 
specificity. G-proteins couple to the C-terminal end, 
which is important for receptor signaling following 
ligand binding. 
Description 
355 amino acids; 41173 Da. 
Expression 
Monocyte/macrophages; T cells; platelets; tonsil B  
lymphocytes; blood derived mast cells, dendritic cells, 
basophils and eosinophils; bone marrow stromal cells; 
microvascular endothelial cells; vascular smooth 
muscle cells. 
Localisation 
Cell membrane; multi-pass membrane protein. 
Function 
Receptor for a C-C type chemokine. Binds to CCL3 
(MIP-1-alpha), CCL5 (RANTES), CCL7 (MCP-3), 
CCL9 (MIP-1-gamma), CCL14 (HCC-1), CCL15 
(MIP-1-delta), CCL16 (HCC-4) and CCL23 (MIP-3), 
and, less efficiently, to MIP-1-beta or MCP-1 and 
subsequently transduces a signal by increasing the 
intracellular calcium ions level. The major function of 
CCR1 is to regulate leukocyte trafficking in 
hematopoiesis and in innate and adaptive immunity. 
Other functions include angiogenic activity, 
ischemia/reperfusion injury, immune-cell 
differentiation, phagocyte activation, and affecting 
stem cell proliferation. 
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Homology 
CCR1 protein contains considerable amino acid 
sequence homology to other C-C chemokines: CCR2B 




CCR1 expression correlates with overall survival in the 
non-germinal center subtype of diffuse large B-cell 
lymphoma. In follicular lymphoma, high levels of 
CCR1 are associated with a shorter survival interval, 
and CCR1 is a marker of an immune switch between 
macrophages and a T cell-dominant response. 
Oncogenesis 
CCR1 is expressed in intraepithelial B cells of human 
tonsil and granulocytic/monocytic cells in the bone 
marrow. Immunohistochemical analysis of 944 cases of 
hematolymphoid neoplasia identified CCR1 expression 
in a subset of B- and T-cell lymphomas, plasma cell 
myeloma, acute myeloid leukemia, and classical 
Hodgkin lymphoma. In 13 patients with chronic 
lymphocytic leukemia (CLL), 9 with hairy cell 
leukemia (HCL), 5 with mantle cell lymphoma (MCL), 
5 with marginal zone B-cell lymphoma (MZL), 6 with 
small lymphocytic lymphoma (SLL), and 5 with 
follicular cell lymphoma (FCL), flow cytometry 
analysis demonstrated that CCR1 was expressed in 
70% of patients with CLL and 40% of those with HCL 
but was lacking in patients with MCL, MZL, SLL, and 
circulating normal B cells.  
Circulating CD3+ T cells derived from healthy 
individuals and acute myelogenous leukemia patients 
with therapy-induced cytopenia after conventional 
chemotherapy or allogeneic stem cell transplantation 
showed no qualitative differences in CCR1 expression, 
that is, low expression for all the three groups. 
Multiple myeloma 
Prognosis 
In 80 multiple myeloma (MM) patients with bone 
marrow samples, patients with active disease showed a 
significantly lower expression of CCR1, CCR2, as well 
as CXCR4 than patients with non-active disease. This 
chemokine receptor expression profile correlated with 
serum beta2-microglobulin, C-reactive protein and 
hemoglobin. Multivariate analysis identified the 
chemokine receptor expression profile as an 
independent prognostic factor. 
Oncogenesis 
Human MM cells express at least three different 
chemokine receptors that are functionally involved in 
MM cell migration, i.e. CCR1, CCR2 and CXCR4, 
some also CCR6 and CXCR3. cDNA arrays identified 
CCR1 and CCR2 are overexpressed in myeloma cells 
compared to autologous B-lymphoblastoid cell lines. 
The expression of CCR1 and the migration to their 
ligands, RANTES and MIP-1alpha, respectively, were 
demonstrated in MM cell lines and primary MM cells. 
Osteoclasts (OCL) secrete high levels of CCL3 and 
MM cells the express CCR1, the interaction between 
which plays a key role in the pathogenesis of MM-
related osteolytic bone disease. Through CCL3-CCR1 
axis OCL cells promote OCL formation and, in turn, 
OCL enhance MM cell proliferation.  
In murine models of MM, MIP-1alpha, an OCL 
stimulatory factor produced by primary MM cells, 
increases bone destruction and tumor burden, by 
interacting with chemokine receptors CCR1 and CCR5 
that widely expressed in human OCL precursors, 
myeloma cell lines, and purified marrow plasma cells 
from MM patients. Neutralizing antibodies to CCR1 or 
CCR5 inhibited MIP-1alpha-induced OCL formation. 
Furthermore, MCP-3, which binds CCR1 but not 
CCR5, and the CCR1-specific antagonist, BX471, 
markedly inhibited OCL formation stimulated with 
MIP-1alpha. Anti-CCR1, anti-CCR5, or BX471 also 
inhibited the upregulation of beta1 integrin myeloma 
cells induced by MIP-1alpha, as well as the adherence 
of myeloma cells to stromal cells and IL-6 production 
by stromal cells in response to myeloma cells.  
The oncogene c-maf is translocated in approximately 
5%-10% of MM. By gene expression profiling, three c-




Hepatic myofibroblast LI90 cells express and secrete 
MCP-1/CCL2. Through its receptors CCR1 and CCR2 
as well, LI90 induces human hepatocellular carcinoma 
(HCC) Huh7 cell migration and invasion, which are 
strongly inhibited by heparin, beta-D-xyloside and anti-
syndecan-1 and -4 antibodies. RANTES/CCL5 strongly 
stimulates the migration and the invasion of Huh7 cells 
by stimulating the tyrosine phosphorylation of focal 
adhesion kinase as well as activating matrix 
metalloproteinase-9, and to a lesser extent that of 
Hep3B cells. The RANTES-induced migration and 
invasion of Huh7 cells are also strongly inhibited by 
anti-CCR1 antibodies and heparin, as well as by beta-d-
xyloside treatment of the cells, suggesting that CCR1 
and glycosaminoglycans are involved in these events. 
We found that the miRNA-mediated knockdown 
expression of CCR1 significantly inhibited the invasive 
ability of and reduced the secretion of MMP-2 in 
hepatocellular carcinoma HCCLM3 cells, but only had 
a minor effect on the cellular proliferation. CCR1 
expression was also detected on primary HCC cells and 
to a lesser degree, on endothelial cells in HCC tissues 
but not in normal liver tissues. Similarly, CCL3 
expression was detected in HCC cells, endothelial cells, 
and to a lesser degree, fibroblast-like cells in HCC 
tissue, whereas only occasional vascular endothelial 
cells and inflammatory cells in normal liver tissues 
were weakly positive for CCL3. IL-1 enhances the 
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local production of CCL3, which interact with CCR1 
expressed on HCC cells, in an autocrine and/or 
paracrine manner. In a murine HCC model, injected 
tumor cells were transfected with HSV-thymidine 
kinase gene and then treated with ganciclovir (GCV). 
GCV treatment induced massive tumor cell apoptosis 
accompanied with intratumoral CCR1+CCR5+ 
dendritic cell infiltration. Tumor-infiltrating T cells and 
macrophages expressed CCL3, suggesting CCR1-
CCL3 play a crucial role in the regulation of 
intratumoral dendritic cell accumulation and the 
subsequent establishment of tumor immunity following 
induction of tumor apoptosis by suicide genes. CCL3 
and CCR1 are also expressed in 2 different models of 
HCC, i.e., N-nitrosodiethylamine (DEN)-induced HCC 
and HCC induced by hepatitis B virus. After DEN 
treatment, tumor foci number and sizes were 
remarkably reduced in CCR1- and CCL3-deficient 
mice, comparing with wild-type (WT) mice. Also, 
tumor angiogenesis markedly diminished, intratumoral 
Kupffer cells number reduced, MMP9 gene expression 
attenuated and MMP9+ cell numbers decreased in 
CCL3- and CCR1-deficient mice, as compared with 
WT mice. These observations suggest the contribution 
of the CCR1-CCL3 axis to HCC progression. 
Colorectal cancer 
Prognosis 
The expression of CCR1 is higher in colorectal 
carcinoma than normal tissues, and correlates with 
lymph node metastasis, deep invasion, poor 
differentiation and advanced Dukes' stage. 
Oncogenesis 
Inactivation of TGF-beta family signaling within colon 
cancer increases CCL9 and promotes recruitment of the 
matrix metalloproteinase-expressing stromal cells that 
carry CCR1. Lack of CCR1 prevents the accumulation 
of MMP-expressing cells at the invasive front and 
suppresses tumor invasion. In a murine model of 
invasive colorectal cancer in which TGF-beta family 
signaling is blocked, CD34+ CCR1+ immature myeloid 
cell is recruited from the bone marrow to the tumor 
invasive front where expression of CCL9 is increased. 
These immature myeloid cells express MMP9, MMP2 
and CCR1 and migrate toward the ligand CCL9. Lack 
of CCR1 prevents accumulation of CD34+ immature 
myeloid cell at the invasive front and suppresses tumor 
invasion. 
Non-small cell lung cancer 
Oncogenesis 
CCR1 expression correlated with the aggressive 
phenotype of the non-small cell lung cancer (NSCLC) 
cells. CCR1 knockdown significantly suppressed the 
invasiveness of NSCLC cells and significantly reduced 
the expression of matrix metalloproteinase-9, but had 
only a minor effect on cell proliferation. 
 
Oral squamous cell carcinoma 
Oncogenesis 
Expression of CCL3 and CCR1 is significant higher in 
oral squamous cell carcinoma compared with the 
normal controls. The percentages of CCL3+ and 
CCR1+ cells were observed to be similar in 
parenchyma and stroma in cases without lymph node 




mRNA for CCR1, -2a, -2b, -3, -4, -5, and -8 was 
detected in cells from human ovarian cancer ascites. 
Further, flowcytometry showed CD14+ macrophages 
within ascites consistently expressed CCR1, -2, and -5, 
and >60% of all T cells expressed CCR1. Although 
ovarian cancer ascitic and blood 
monocyte/macrophages express CCR1, they failed to 
migrate in response to the RANTES. Compared with 
that of normal blood, cell surface expression level for 
CCR1 was higher in ascites. In a monocytic cell line in 
vitro, CCR1 mRNA expression was increased 5-fold by 
hypoxia. In 25 patients with ovarian cancer, CCR1 was 
detected in samples from 75% of patients, where CCR1 
localised to macrophages and lymphocytes, and there 




Androgen receptor negative human prostate cancer cell 
line DU-145 cells selectively expressed CXCR4 and 
CCR1 at high levels compared with DU-145/AR cells 
that express androgen receptor. DU-145 showed 
vigorous migratory responses to CXCL12 and CCL3. 
In contrast, neither CXCL12 nor CCL3 affected the 
migration of DU-145/AR cells. 
Breast cancer 
Oncogenesis 
The expression of CCR5 was higher than that of CCR1 
in the peripheral blood mononuclear cells (PBMC) of 
healthy women, while the PBMC of the breast cancer 
patients showed overexpression of CCR1 and 
downregulation of CCR5. The differential effects of 
MIP-1alpha and MIP-1beta on the PBMC of healthy 
women and breast cancer patients correlated with the 
expression levels of CCR1 and CCR5 in these 
monocytes. In murine model of breast cancer, CCL5 
(RANTES) was produced by the tumor cells, and its 
receptors, CCR1 and CCR5, were expressed by the 
infiltrating leukocytes. In mice treatment with Met-
CCL5, an antagonist of CCR1 and CCR5, the volume 
and weight of tumors were significantly decreased 
compared with control-treated tumors.  
The total cell number obtained after collagenase  
 






Atlas Genet Cytogenet Oncol Haematol. 2011; 15(1)  5 
digestion was decreased in Met-CCL5-treated tumors 
as was the proportion of infiltrating macrophages. 
Furthermore, chemokine antagonist treatment increased 
stromal development and necrosis. 
Glioma 
Oncogenesis 
Co-cultured human glioma U87 cells induced an 
activated phenotype in HUVECs. These tumour-
activated endothelial cells coordinately expressed 
matching pairs of receptors/ligands were found to be, 
including CCR1-RANTES axis. 
Osteogenic sarcoma 
Oncogenesis 
The activities of phospholipase C (PLC), protein kinase 
C delta (PKCdelta) and NF-kappaB were enhanced by 
Lkn-1 (CCL15) stimulation on CCR1+ human 
osteogenic sarcoma cells. Inhibitors of G protein, PLC, 
PKCdelta and NF-kappaB inhibited the chemotactic 
activity of Lkn-1 on CCR1+ osteogenic sarcoma cells 
indicating that Lkn-1-induced chemotaxis involving 
these signaling pathways. 
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